Determination of the target population in early benefit assessments in Germany : challenges for non-small-cell lung cancer
C. ten Thoren, C. Balg, J. Gibbert, S. Mostardt, M. Ripoll, D. Schierbaum, S. Schiller, A. Schwalm
| Year of publication: |
2020
|
|---|---|
| Authors: | TenThoren, C. ; Balg, C. ; Gibbert, J. ; Mostardt, S. ; Ripoll, M. ; Schierbaum, D. ; Schiller, S. ; Schwalm, A. |
| Published in: |
The European journal of health economics : HEPAC ; health economics in prevention and care. - Berlin : Springer, ISSN 1618-7598, ZDB-ID 2045253-6. - Vol. 21.2020, 6, p. 881-893
|
| Subject: | Non-small-cell lung cancer | NSCLC | Early benefit assessment | New drugs | Target population | Krebskrankheit | Cancer | Deutschland | Germany | Arzneimittel | Pharmaceuticals | Kosten-Nutzen-Analyse | Cost-benefit analysis |